NRAS and acute myeloid leukemia: To investigate whether miR-708 is a suitable drug for cancers driven by NRAS mutation, we collected three cell lines carrying NRAS mutation from different cancer types, SK-MEL-2, THP-1, and H1299, which belong to malignant melanoma, AML, and non-small cell lung cancer (NSCLC) respectively (Fig 1A).